ArticleJournal of clinical medicine2019
Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases.The Cochrane database of systematic reviews · 2024Pooled it
- Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: A systematic review and meta-analysis.Journal of neuroendocrinology · 2021Pooled it
- Electrocoagulation for liver metastases.The Cochrane database of systematic reviews · 2021Pooled it
- Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.The Cochrane database of systematic reviews · 2020Pooled it
- Percutaneous ethanol injection for liver metastases.The Cochrane database of systematic reviews · 2020Pooled it
- Surgical Approach to Liver Metastasis from Gastroenteropancreatic Neuroendocrine Tumors in the Era of Precision Oncology.Cancers · 2026Review
- Liver transplantation for the treatment of neuroendocrine liver metastases.Frontiers in surgery · 2025Review
- Current Management of Neuroendocrine Tumour Liver Metastases.Current oncology reports · 2024Review
- Evolution of Liver Transplantation Indications: Expanding Horizons.Medicina (Kaunas, Lithuania) · 2024Review
- The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.Current treatment options in oncology · 2023Review
- Editorial on "Uncommon indications for associating liver partition and portal vein ligation for staged hepatectomy: a systematic review".Hepatobiliary surgery and nutrition · 2022Article
- How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.Current oncology reports · 2022Review
- Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms.World journal of surgery · 2021Article
- Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands.World journal of surgery · 2021Article
- Surgical Management of Neuroendocrine Tumor Liver Metastases.Surgical oncology clinics of North America · 2021Review
- Currently available treatment options for neuroendocrine liver metastases.Annals of gastroenterology · 2021Review
- Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary surgery and nutrition · 2020Review
- Surgical management of pancreatic neuroendocrine liver metastases.Journal of gastrointestinal oncology · 2020Review
- Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strong evidence comparing different treatment options for liver metastases (LM) arising from gastroenteropancreatic neuroendocrine tumours (GEP-NET) is lacking. The aim of this study was to determine which intervention for LMs from GEP-NETs shows the longest overall survival (OS). A systematic search was performed in MEDLINE, Embase and the Cochrane Library in February 2018. Studies reporting on patients with LMs of any grade of sporadic GEP-NET comparing two intervention groups were included for analysis. Meta-analyses were performed where possible. Eleven studies, with a total of 1108, patients were included; 662 patients had LM from pancreatic NETs (pNET), 164 patients from small-bowel NETs (SB-NET) and 282 patients of unknown origin. Improved 5-year OS was observed for surgery vs. chemotherapy (OR .05 95% CI [0.01, 0.21]
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.